Evidence map›Paper›PMID 42163152›Full record

ArticleBMC infectious diseases2026

Relapse of HIV-associated multicentric Castleman disease temporally associated with acute coronavirus disease 2019: a case report.

Hiroki Yamamoto, Kazuaki Fukushima, Yota Aizawa, Kohei Ukai, Shota Kodaira, Yukari Nishikawa, Shuhei Tada, Seowoong Jung, Masaru Tanaka, Taiichiro Kobayashi and 6 more

Abstract readCase Reports
In one paragraph

Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Hiroki YamamotoDepartment of Infectious Diseases, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan.
Kazuaki FukushimaDepartment of Infectious Diseases, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan. fukushima-ngi@umin.ac.jp.
Yota AizawaDepartment of Infectious Diseases, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan.
Kohei UkaiDepartment of Infectious Diseases, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan.
Shota KodairaDepartment of Infectious Diseases, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan.
Yukari NishikawaDepartment of Infectious Diseases, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan.
Shuhei TadaDepartment of Infectious Diseases, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan.
Seowoong JungDepartment of Infectious Diseases, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan.
Masaru TanakaDepartment of Infectious Diseases, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan.
Taiichiro KobayashiDepartment of Infectious Diseases, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan.
Ryoko SekiyaDepartment of Infectious Diseases, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan.
Keishiro YajimaDepartment of Infectious Diseases, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan.
Atsushi AjisawaDepartment of Infectious Diseases, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan.
Ryu GomikawaDepartment of Pathology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan.
Tsunekazu HishimaDepartment of Pathology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan.
Akifumi ImamuraDepartment of Infectious Diseases, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHuman immunodeficiency virus-associated multicentric Castleman disease (HIV-MCD), a human herpesvirus 8 (HHV-8)-driven lymphoproliferative disorder affecting individuals infected by HIV, typically exhibits a relapsing-remitting course and can be fatal. The incidence of HIV-MCD is on the rise while that of Kaposi's sarcoma, another HHV-8-associated disease, has been declining. Although an increasing number of studies have reported relapses of human herpesvirus-associated diseases and HIV-negative MCD following coronavirus disease 2019 (COVID-19), to the best of our knowledge there are no reports of HIV-MCD relapses. CASE PRESENTATION: A 75-year-old male patient with well-controlled HIV infection and pre-existing HIV-MCD experienced a relapse of HIV-MCD temporally associated with infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). He had a two-month history of persistent cough and received the diagnosis of mild COVID-19 based on positivity for SARS-CoV-2 on a polymerase chain reaction test and characteristic findings on computed tomography. Although the COVID-19 resolved with remdesivir therapy, the patient subsequently experienced a fever, generalized lymphadenopathy, splenomegaly, and thrombocytopenia. A lymph node biopsy confirmed a MCD relapse. The patient improved markedly after rituximab therapy.

conclusionThis case is the first to report a temporal association between SARS-CoV-2 infection and HIV-MCD relapse. While a direct causal relationship cannot be established, the clinical course is consistent with the hypothesis that SARS-CoV-2 infection may have contributed to HHV-8 reactivation and MCD relapse. Further case series and mechanistic studies are needed to evaluate this potential association.

Indexed as

Castleman DiseaseCOVID-19HIV InfectionsAgedHerpesvirus 8, HumanHumansMaleRecurrenceSARS-CoV-2Coronavirus disease 2019Human herpesvirus 8Human immunodeficiency virusMulticentric Castleman diseaseSevere acute respiratory syndrome coronavirus 2

Identifiers

PMID42163152
PMCPMC13371506

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.